arrow
S

Seán Gaine

mater misericordiae university hospital
H指数:55
被引数:2.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension

评估帕萨生帕戈口服制剂在肺动脉高压中的疗效:来自GRIPHON及其开放标签扩展研究的完整观察期关于生存、安全性和给药方案模式的见解

2025-11-140
PRE
Treatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE Europe

Edoxaban治疗静脉血栓栓塞超过18个月: 来自etna-vte Europe的结果

2025-01-160
OAAI
Changes in REVEAL Lite 2 risk status are associated with long-term outcomes in patients with pulmonary arterial hypertension: A post-hoc analysis of the GRIPHON study

REVEAL Lite 2风险状态的变化与肺动脉高压患者的长期预后相关: GRIPHON研究的事后分析

2024-12-010
PRE
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG)

2022欧洲心脏病学会 (ESC) 和欧洲呼吸学会 (ERS) 肺动脉高压诊断和治疗工作组制定的ESC/ERS肺动脉高压诊断和治疗指南。由国际心肺移植学会 (ISHLT) 和欧洲罕见呼吸系统疾病参考网络 (ern-lung) 认可

2022-08-26370
OA
Non-severe COVID-19 is associated with endothelial damage and hypercoagulability despite pharmacological thromboprophylaxis
2022-04-0117
OAAI